Shernan G. Holtan - Concepedia

Author

Shernan G. Holtan

Also Known As

Holtan, Shernan, Holtan, Shernan Grace, S G Holtan, S Holtan, S. G. Holtan, S. Holtan, S.G. HOLTAN, S.G. Holtan, Shernan G Holtan, Shernan G. Holtan

467

Publications

6.8K

Citations

H-Index

106

Concepts

All Affiliations

University of Minnesota Mayo Clinic University of Minnesota Medical Center Dana-Farber Cancer Institute Moffitt Cancer Center

About

Shernan G. Holtan is an author at University of Minnesota specializing in medicine, immunology, and transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	30	1.4K
2	Health Sciences	10	10	484
3	Public Health	4	4	103
4	Biostatistics	2	2	30
5	Allergy	1	1	32

Shernan G. Holtan

100

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation Shernan G. Holtan, Todd E. DeFor, Aleksandr Lazaryan, Blood	2015	482
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis Javier Bolaños‐Meade, Mehdi Hamadani, Juan Wu, New England Journal of Medicine	2023	460
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203) Javier Bolaños‐Meade, Ran Reshef, Raphael Fraser, The Lancet Haematology Versus TacrolimusTransplantationImmunosuppressive TherapyImmunologyHematology	2019	274
A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality Margaret L. MacMillan, Marie Robin, Andrew C. Harris, Biology of Blood and Marrow Transplantation	2015	272
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors Kim Margolin, Chihiro Morishima, Vamsidhar Velcheti, Clinical Cancer Research	2018	199
Immunomodulation in COVID-19 Nicholas E. Ingraham, Sahar Lotfi‐Emran, Beth K Thielen, The Lancet Respiratory Medicine	2020	181
Fetal Sex‐Based Differences in Maternal Hormones, Angiogenic Factors, and Immune Mediators During Pregnancy and the Postpartum Period Elizabeth Ann L. Enninga, Wendy K. Nevala, Douglas J. Creedon, American Journal of Reproductive Immunology	2014	171
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report Carrie L. Kitko, Joseph Pidala, Hélène Schoemans, Transplantation and Cellular Therapy Solid Organ TransplantationTransplantation MedicinePathologyTranslational MedicineChronic Gvhd	2021	156
Diagnosis of Obesity by Primary Care Physicians and Impact on Obesity Management Aditya Bardia, Shernan G. Holtan, Jeffrey M. Slezak, Mayo Clinic Proceedings ObesityMetabolic SyndromeFamily MedicinePrimary CarePrimary Care Physicians	2007	146
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Journal for ImmunoTherapy of Cancer	2019	142

Page 1